At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARQT Arcutis Biotherapeutics Inc.
Trading 12-11 15:12:08 EST
29.57
-0.20
-0.67%
High30.14Low29.32Vol1.29M
Open29.81D1 Closing29.77Amplitude2.75%
Mkt Cap3.62BTradable Cap2.61BTotal Shares122.49M
T/O38.50MT/O Rate1.47%Tradable Shares88.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Simply Wall St.  ·  12-09 20:12
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Arcutis Biotherapeutics Files Initial Beneficial Ownership Statement for Director Amit Munshi
Reuters  ·  12-09 09:01
Arcutis Biotherapeutics Files Initial Beneficial Ownership Statement for Director Amit Munshi
Amit Munshi Joins Arcutis Board as Bhaskar Chaudhuri Retires
Reuters  ·  12-09 05:00
Amit Munshi Joins Arcutis Board as Bhaskar Chaudhuri Retires
Press Release: Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Dow Jones  ·  12-09 05:00
Press Release: Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares
Reuters  ·  12-04
Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares
U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams
Reuters  ·  11-28
U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams
Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $37 From $32
THOMSON REUTERS  ·  11-28
Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $37 From $32
Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
TIPRANKS  ·  11-27
Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
Arcutis Biotherapeutics (ARQT) Is Up 17.5% After FDA Review Accepted for Pediatric ZORYVE Expansion - Has The Bull Case Changed?
Simply Wall St.  ·  11-25
Arcutis Biotherapeutics (ARQT) Is Up 17.5% After FDA Review Accepted for Pediatric ZORYVE Expansion - Has The Bull Case Changed?
Arcutis Biotherapeutics CEO Todd Watanabe Reports Disposal of Common Shares
Reuters  ·  11-25
Arcutis Biotherapeutics CEO Todd Watanabe Reports Disposal of Common Shares
Director Halley E. Gilbert Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares
Reuters  ·  11-22
Director Halley E. Gilbert Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares
Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
Reuters  ·  11-20
Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  11-20
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
FDA Accepts Arcutis Supplemental Application for ZORYVE Cream in Young Children with Plaque Psoriasis
Reuters  ·  11-17
FDA Accepts Arcutis Supplemental Application for ZORYVE Cream in Young Children with Plaque Psoriasis
Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Date for June 29, 2026
THOMSON REUTERS  ·  11-17
Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Date for June 29, 2026
FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
THOMSON REUTERS  ·  11-17
FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
Executive VP & Chief Commercial Officer Of Arcutis Biotherapeutics Sold 40% Of Their Shares
Simply Wall St.  ·  11-14
Executive VP & Chief Commercial Officer Of Arcutis Biotherapeutics Sold 40% Of Their Shares
Arcutis Biotherapeutics Completes Enrollment for Phase 2 Study of Investigational Treatment for Atopic Dermatitis
MT Newswires Live  ·  11-13
Arcutis Biotherapeutics Completes Enrollment for Phase 2 Study of Investigational Treatment for Atopic Dermatitis
BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
Reuters  ·  11-13
BRIEF-Arcutis Canada Says Health Canada Approves ZORYVE Foam 0.3% For Scalp, Body Psoriasis For Adults & Adolescents 12 & Older
Refile-Arcutis Canada: Health Canada Approves Zoryve Foam 0.3% for Scalp, Body Psoriasis for Adults & Adolescents 12 & Older (Removes Extra Words)
THOMSON REUTERS  ·  11-13
Refile-Arcutis Canada: Health Canada Approves Zoryve Foam 0.3% for Scalp, Body Psoriasis for Adults & Adolescents 12 & Older (Removes Extra Words)

Introduction

Company Name.
Arcutis Biotherapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Issue price:
--